Select Publications
Journal articles
2023, 'Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.', Patient Relat Outcome Meas, 14, pp. 111 - 126, http://dx.doi.org/10.2147/PROM.S297301
,2022, 'Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes', Clinical Cancer Research, 28, pp. 5383 - 5395, http://dx.doi.org/10.1158/1078-0432.CCR-22-1206
,2022, 'CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors', Journal of Experimental and Clinical Cancer Research, 41, http://dx.doi.org/10.1186/s13046-022-02570-4
,2022, 'Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study', Journal of Translational Medicine, 20, http://dx.doi.org/10.1186/s12967-022-03754-4
,2022, 'The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer', Nature Genetics, 54, pp. 1853 - 1864, http://dx.doi.org/10.1038/s41588-022-01230-9
,2022, 'Copy number variants are ovarian cancer risk alleles at known and novel risk loci', Journal of the National Cancer Institute, 114, pp. 1533 - 1544, http://dx.doi.org/10.1093/jnci/djac160
,2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical and Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/OGX.0000000000001075
,2022, 'What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer', Gynecologic Oncology, 166, pp. 410 - 416, http://dx.doi.org/10.1016/j.ygyno.2022.07.004
,2022, 'A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer', GYNECOLOGIC ONCOLOGY, 166, pp. S160 - S160, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892330200198&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer', Gynecologic Oncology, 166, pp. 254 - 262, http://dx.doi.org/10.1016/j.ygyno.2022.05.024
,2022, 'Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis', European Journal of Cancer, 170, pp. 169 - 178, http://dx.doi.org/10.1016/j.ejca.2022.04.022
,2022, 'Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients', International Journal of Gynecological Cancer, 32, pp. 906 - 912, http://dx.doi.org/10.1136/ijgc-2021-003009
,2022, 'TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members', Journal of Clinical Oncology, 40, pp. 2036 - 2047, http://dx.doi.org/10.1200/JCO.21.02108
,2022, 'Risk of Peritoneal Cancer after Risk-Reducing Bilateral Salpingo-Oophorectomy for Women with Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?', Journal of Clinical Oncology, 40, pp. 1850 - 1852, http://dx.doi.org/10.1200/JCO.22.00325
,2022, 'Germline BRCA variants, lifestyle and ovarian cancer survival', Gynecologic Oncology, 165, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2022.03.020
,2022, 'The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 33, pp. 593 - 601, http://dx.doi.org/10.1016/j.annonc.2022.02.222
,2022, 'Impact of Homologous Recombination Status and Responses with Veliparib Combined with First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study', Journal of Bone and Joint Surgery, 77, pp. 277 - 278, http://dx.doi.org/10.1097/01.ogx.0000827620.82650.68
,2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319
,2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y
,2022, 'The validity of progression-free survival 2 as a surrogate trial end point for overall survival', Cancer, 128, pp. 1449 - 1457, http://dx.doi.org/10.1002/cncr.34085
,2022, 'Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial', Annals of Oncology, 33, pp. 299 - 309, http://dx.doi.org/10.1016/j.annonc.2021.11.018
,2022, 'Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)', Gynecologic Oncology, 164, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2021.12.006
,2022, 'Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study', Gynecologic Oncology, 164, pp. 245 - 253, http://dx.doi.org/10.1016/j.ygyno.2021.12.003
,2022, 'Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial', Gynecologic Oncology, 164, pp. 278 - 287, http://dx.doi.org/10.1016/j.ygyno.2021.12.012
,2022, 'EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)', Future Oncology, 18, pp. 3481 - 3492, http://dx.doi.org/10.2217/fon-2022-0666
,2022, 'Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221112822
,2022, 'Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation', Cancer Treatment and Research Communications, 30, http://dx.doi.org/10.1016/j.ctarc.2021.100504
,2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075
,2021, 'Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel', Scientific Reports, 11, pp. 22884, http://dx.doi.org/10.1038/s41598-021-02439-0
,2021, 'Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 1721 - 1731, http://dx.doi.org/10.1016/S1470-2045(21)00531-3
,2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, 163, pp. 524 - 530, http://dx.doi.org/10.1016/j.ygyno.2021.09.010
,2021, 'Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkab090
,2021, 'Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial', Therapeutic Advances in Medical Oncology, 13, http://dx.doi.org/10.1177/17588359211059601
,2021, 'Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence', Cancer Prevention Research, 14, pp. 983 - 994, http://dx.doi.org/10.1158/1940-6207.CAPR-21-0141
,2021, 'Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment', Gynecologic Oncology, 163, pp. 398 - 407, http://dx.doi.org/10.1016/j.ygyno.2021.08.022
,2021, 'EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB plus OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 31, pp. A139 - A140, http://dx.doi.org/10.1136/ijgc-2021-IGCS.350
,2021, 'Mendelian randomisation study of smoking exposure in relation to breast cancer risk', British Journal of Cancer, 125, pp. 1135 - 1145, http://dx.doi.org/10.1038/s41416-021-01432-8
,2021, 'A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial', Gynecologic Oncology, 163, pp. 72 - 78, http://dx.doi.org/10.1016/j.ygyno.2021.07.024
,2021, 'Cancer of the ovary, fallopian tube, and peritoneum: 2021 update', International Journal of Gynecology and Obstetrics, 155, pp. 61 - 85, http://dx.doi.org/10.1002/ijgo.13878
,2021, 'Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial', Gynecologic Oncology, 163, pp. 41 - 49, http://dx.doi.org/10.1016/j.ygyno.2021.07.016
,2021, 'Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin/paclitaxel for gBRCA advanced breast cancer (BROCADE3 Crossover)', Clinical Cancer Research, 27, pp. 4983 - 4993, http://dx.doi.org/10.1158/1078-0432.CCR-21-0748
,2021, 'Concurrent maternal malignancy and fetal trisomy detected using genome-wide noninvasive prenatal screening', Prenatal Diagnosis, 41, pp. 1273 - 1276, http://dx.doi.org/10.1002/pd.6020
,2021, 'Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial', European Journal of Cancer, 154, pp. 35 - 45, http://dx.doi.org/10.1016/j.ejca.2021.05.037
,2021, 'Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 1669 - 1680, http://dx.doi.org/10.1158/1055-9965.EPI-20-1817
,2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', Obstetrical and Gynecological Survey, 76, pp. 535 - 536, http://dx.doi.org/10.1097/OGX.0000000000000962
,2021, 'Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy', European Journal of Cancer, 154, pp. 190 - 200, http://dx.doi.org/10.1016/j.ejca.2021.06.024
,2021, 'Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial', Gynecologic Oncology, 162, pp. 375 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.05.031
,2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y
,2021, 'Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis', Cancer, 127, pp. 2432 - 2441, http://dx.doi.org/10.1002/cncr.33517
,2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for ImmunoTherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255
,